BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/20/2014 10:04:00 AM | Browse: 1266 | Download: 1418
 |
Received |
|
2013-11-03 19:51 |
|
Peer-Review Started |
|
2013-11-04 19:50 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2014-01-12 17:35 |
|
Revised |
|
|
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2014-06-11 12:25 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2014-06-11 12:33 |
|
Articles in Press |
|
2014-06-11 14:44 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2014-09-28 17:47 |
|
Publish the Manuscript Online |
|
2014-10-20 10:04 |
| Category |
Hematology |
| Manuscript Type |
Minireviews |
| Article Title |
Myelofibrosis: Prognostication and cytoreductive treatment
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Margherita Maffioli, Domenica Caramazza, Barbara Mora, Michele Merli and Francesco Passamonti |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Francesco Passamonti, MD
Division of Hematology, Department of Medicine
University Hospital Ospedale di Circolo e Fondazione Macchi
Viale L. Borri 57, 21100 Varese, Italy
Tel/Fax: +39 0332 393 648. E-mail francesco.passamonti@ospedale.varese.it |
| Key Words |
Myelofibrosis; ruxolitinib; fedratinib; momelotinib; prognosis |
| Core Tip |
The paper provides information on recent prognostication advances in myelofibrosis. In addition, efficacy/safety of ruxolitinib, fedratinib and momelotinib are discussed in detail |
| Publish Date |
2014-10-20 10:04 |
| Citation |
Maffioli M, Caramazza D, Mora B, Merli M, Passamonti F. Myelofibrosis: Prognostication and cytoreductive treatment. World J Hematol 2014; 3(3): 85-92 |
| URL |
http://www.wjgnet.com/2218-6204/full/v3/i3/85.htm |
| DOI |
http://dx.doi.org/10.5315/wjh.v3.i3.85 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
